Virax Biolabs Group (VRAX) Competitors $0.87 -0.06 (-6.05%) Closing price 07/15/2025 03:58 PM EasternExtended Trading$0.87 +0.00 (+0.34%) As of 07/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. SNPX, PHXM, TLPH, CLDI, ADXN, GOVX, GLYC, APRE, XFOR, and CYCNShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Synaptogenix (SNPX), PHAXIAM Therapeutics (PHXM), Talphera (TLPH), Calidi Biotherapeutics (CLDI), Addex Therapeutics (ADXN), GeoVax Labs (GOVX), GlycoMimetics (GLYC), Aprea Therapeutics (APRE), X4 Pharmaceuticals (XFOR), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Synaptogenix PHAXIAM Therapeutics Talphera Calidi Biotherapeutics Addex Therapeutics GeoVax Labs GlycoMimetics Aprea Therapeutics X4 Pharmaceuticals Cyclerion Therapeutics Synaptogenix (NASDAQ:SNPX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Do analysts rate SNPX or VRAX? Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 244.83%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, SNPX or VRAX? Synaptogenix has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Does the media prefer SNPX or VRAX? In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of 1.89 beat Synaptogenix's score of 1.87 indicating that Virax Biolabs Group is being referred to more favorably in the news media. Company Overall Sentiment Synaptogenix Very Positive Virax Biolabs Group Very Positive Is SNPX or VRAX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -115.28% -58.31% Virax Biolabs Group N/A N/A N/A Do insiders & institutionals believe in SNPX or VRAX? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, SNPX or VRAX? Virax Biolabs Group has higher revenue and earnings than Synaptogenix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$10.08-1.03Virax Biolabs Group$10K377.58-$6.06MN/AN/A SummaryVirax Biolabs Group beats Synaptogenix on 10 of the 11 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.02M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.2228.5419.58Price / Sales377.58299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.697.568.145.54Net Income-$6.06M-$55.11M$3.24B$257.73M7 Day Performance-5.80%3.81%0.18%-0.08%1 Month Performance-0.03%11.60%5.96%8.09%1 Year Performance-32.03%-2.11%26.24%13.02% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.0896 of 5 stars$0.87-6.0%$3.00+244.8%-23.0%$4.02M$10K0.005Positive NewsSNPXSynaptogenix0.3165 of 5 stars$7.63-10.2%$14.00+83.5%+130.2%$10.61MN/A-0.764Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049TLPHTalphera2.3684 of 5 stars$0.50+8.6%$5.00+894.8%-52.5%$10.31M$27K-1.1219CLDICalidi Biotherapeutics0.5631 of 5 stars$0.32+33.6%N/A-67.1%$10.21MN/A0.0038High Trading VolumeADXNAddex Therapeutics2.5146 of 5 stars$9.52+1.5%$30.00+215.1%+8.5%$10.09M$460K-28.0030Positive NewsGap DownGOVXGeoVax Labs2.215 of 5 stars$0.63+25.4%$11.10+1,661.9%-75.4%$10.04M$3.95M-0.1710Analyst UpgradeHigh Trading VolumeGLYCGlycoMimetics0.5141 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading VolumeAPREAprea Therapeutics2.9031 of 5 stars$1.80+4.0%$15.50+761.1%-58.4%$9.95M$1.50M-0.767Gap UpXFORX4 Pharmaceuticals4.9263 of 5 stars$1.69flat$72.33+4,192.8%-93.1%$9.76M$2.56M0.7980Gap UpHigh Trading VolumeCYCNCyclerion Therapeutics2.5364 of 5 stars$3.01-2.6%N/A+8.9%$9.66M$2M-2.5930News Coverage Related Companies and Tools Related Companies Synaptogenix Competitors PHAXIAM Therapeutics Competitors Talphera Competitors Calidi Biotherapeutics Competitors Addex Therapeutics Competitors GeoVax Labs Competitors GlycoMimetics Competitors Aprea Therapeutics Competitors X4 Pharmaceuticals Competitors Cyclerion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRAX Stock Alerts